Evidence map›Paper›PMID 35995900›Full record

ArticleJournal of digital imaging2022

An Efficient Optimization Approach for Glioma Tumor Segmentation in Brain MRI.

Zeynab Barzegar, Mansour Jamzad

Open access · greenAbstract read
In one paragraph

Article in Journal of digital imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zeynab BarzegarSharif University of Technology, Tehran, Iran.ORCID 0000-0001-7834-2412
Mansour JamzadSharif University of Technology, Tehran, Iran. jamzad@sharif.edu.
Sharif University of Technology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is an aggressive type of cancer that develops in the brain or spinal cord. Due to many differences in its shape and appearance, accurate segmentation of glioma for identifying all parts of the tumor and its surrounding cancerous tissues is a challenging task. In recent researches, the combination of multi-atlas segmentation and machine learning methods provides robust and accurate results by learning from annotated atlas datasets. To overcome the side effects of limited existing information on atlas-based segmentation, and the long training phase of learning methods, we proposed a semi-supervised unified framework for multi-label segmentation that formulates this problem in terms of a Markov Random Field energy optimization on a parametric graph. To evaluate the proposed framework, we apply it to publicly available BRATS datasets, including low- and high-grade glioma tumors. Experimental results indicate competitive performance compared to the state-of-the-art methods. Compared with the top ranked methods, the proposed framework obtains the best dice score for segmenting of "whole tumor" (WT), "tumor core" (TC ) and "enhancing active tumor" (ET) regions. The achieved accuracy is 94[Formula: see text] characterized by the mean dice score. The motivation of using MRF graph is to map the segmentation problem to an optimization model in a graphical environment. Therefore, by defining perfect graph structure and optimum constraints and flows in the continuous max-flow model, the segmentation is performed precisely.

Indexed as

Brain NeoplasmsGliomaAlgorithmsBrainHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingContinuous max-flow modelGlioma brain tumorMRF energy optimizationMulti-atlas segmentationMulti-modal brain MRI

Identifiers

PMID35995900
PMCPMC9712883
OpenAlexW4292707199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.